MedTrace Logo

Study of AZD2811 + Durvalumab in ES-SCLC

NCT04745689 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-04-24

Study results available
· View outcomes & findings →

Summary

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.

Conditions

  • Small-Cell Lung Cancer

Interventions

DRUG

Carboplatin

IV infusions through induction phase if chosen by Investigator.

DRUG

Cisplatin

IV infusions through induction phase if chosen by Investigator.

DRUG

Etoposide

IV infusions through induction phase.

DRUG

AZD2811

IV infusions through maintenance phase until PD or other discontinuation criteria.

DRUG

Durvalumab

IV infusions through induction phase. IV infusions through maintenance phase until PD or other discontinuation criteria.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2022-06-18
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04745689 on ClinicalTrials.gov